Stay on Top of Enterprise Technology Trends
Get updates impacting your industry from our GigaOm Research Community
23andMe, the Google-backed personalized genetics company, has raised $11 million worth of a $24.26 million second round, peHUB reports. The regulatory filing didn’t list the new investors; Genentech, New Enterprise Associates and Mohr Davidow Ventures (MDV) all joined Google (NSDQ: GOOG) as backers of the startup’s first round.
Founded by Anne Wojcicki (wife of Google co-founder Sergey Brin), 23andMe lets people explore their genetic makeup online; customers order a kit, mail in a saliva sample and can access their analysis (including details like health traits and ancestry) in about 6-8 weeks. The service costs about $400; competitors include Bioresolve and Navigenics.
23andMe recently got a major endorsement by being featured on the Oprah Winfrey Show, but there has been some controversy: both California and New York cracked down on the startup (and its rivals) last year, requiring proof of federal and state certification for genetic testing — and proof that the were only being conducted upon a physician’s permission (via TechCrunch). peHUB also cites a source that says MDV sold back its small stake in 23andMe once it invested in Navigenics; we’ve confirmed that MDV does have a stake in the rival genetics tech firm.